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1. New Board Member Appointments:
The month of July brought a record number of new mem-
bers to the Massachusetts Board of Registration in Pharmacy 
with the appointment of the following members:
Donald D. Accetta, MD, Allergy and Asthma Care, PC; 
Joel R. Berman, RPh, director of pharmacy operations, 
Stop & Shop Pharmacy; George A. Cayer, RPh, director 
of pharmacy operations, PharMerica; William A. Gouveia, 
RPh, MS, director of pharmacy, Tufts-New England Medi-
cal Center; and Sophia Pasedis, RPh, PharmD, director of 
pharmacy, Mass Eye & Ear Infirmary.
2. New Board Positions Announcement
1. Leo A. McKenna III, RPh, PharmD, was recently 
hired as the Board’s full-time continuing quality im-
provement coordinator. Leo’s position will be to as-
sist on a medication error triage committee, develop 
educational outreach programs, serve as a resource 
to the regulated community in process improvement 
efforts, and to survey, where appropriate, health care 
systems where pharmaceutical care services are be-
ing provided.
2. Samuel J. Penta, RPh, was recently hired as an 
investigator for the Board. Sam will respond to 
consumer complaints and investigate complaints of 
drug diversion, substance abuse, and other violations 
of Board of Pharmacy Regulations. In addition, Sam 
will conduct assigned inspections of community 
pharmacies, nuclear pharmacies, wholesale distribu-
tors, and other licensed premises.
3. Board and Department of Public Health – 
Drug Control Program Adopt New  
Joint Policy 2005-1 
“Continuation of drug therapy upon discontinuance of a 
practitioner’s practice.”
When a pharmacist becomes aware that a practitioner, 
or other person authorized to prescribe in accordance with 
M. G. L. c. 94C, has ceased to practice for any reason and 
that the practitioner-patient relationship has ended, existing 
drug therapy may still need to be continued. Therefore, a 
pharmacist may, pursuant to a prescription previously issued 
by that practitioner or other authorized prescriber and in the 
exercise of good professional judgment, dispense remaining 
refills of a prescription up to a maximum ninety day supply, 
to enable the patient to establish a relationship with another 
practitioner. Refills authorized pursuant to this policy may 
not be dispensed in quantities greater than a thirty day supply 
in a single filling, except where patient insurance coverage 
requires dispensing of a sixty or ninety day supply. (adopted 
October 12, 2004)
4. From the President’s Desk
The role of pharmacy technicians has evolved into be-
coming an integral element of safety and success in the pre-
scription-filling process. In 2002, the Massachusetts Board 
began the process of registering pharmacy technicians as an 
opportunity to allow the expansion of their role to improve 
the practice of pharmacy and enhance public safety.
At this time, all pharmacy personnel acting in the capac-
ity of a pharmacy technician must be registered with the 
Board. Newly hired technicians are considered “technicians 
in training” for the first 500 hours of employment, but must 
register with the Board before they achieve 1,000 hours of 
employment. The registration process allows the Board 
to verify their background, experience, training and skills 
evaluation. 
The Board does not require but certainly encourages all 
technicians to become nationally certified. The current na-
tionally recognized certifying body is the Pharmacy Techni-
cian Certification Board (PTCB). Pharmacies who employ 
PTCB-certified technicians could increase the number of 
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New Over-the-Counter Product Labeling 
On March 24, 2004, Food and Drug Administration (FDA) 
passed final rulings requiring content labeling for over-the 
counter (OTC) medications that contain levels of calcium, mag-
nesium, sodium, or potassium that might be harmful to persons 
with certain underlying medical conditions. The final rule was 
effective April 23, 2004, with compliance expected by Septem-
ber 24, 2005. The labeling changes for oral OTC products were 
deemed necessary as persons with certain medical conditions 
such as heart disease, hypertension, kidney disease, kidney 
stones, or other medical conditions could worsen their condition 
upon consumption of these products. For example, OTC use of 
medications containing potassium may cause hyperkalemia in 
persons with compromised renal function. Under the new rules, 
oral OTC medications must state the exact amount of a particular 
ingredient in each dose if they contain:
 5 mg or more of sodium in a single dose,
 20 mg or more of calcium in a single dose,
 8 mg or more of magnesium in a single dose, or 
 5 mg or more of potassium in a single dose.
The rules also require warnings to alert consumers on sodium-, 
calcium-, magnesium-, or potassium-restricted diets to consult 
their physician before using oral products that contain maximum 
daily doses of:
 more than 140 mg sodium,
 more than 3.2 grams calcium,
 more than 600 mg magnesium, or 
 more than 975 mg potassium.
Currently the new label requirements do not include mouth 
rinses, fluoride toothpastes, or mouth washes. Detailed infor-
mation on the rulings can be found in the Federal Register 
at www.fda.gov/OHRMS/DOCKETS/98fr/04-6479.htm and 
www.fda.gov/OHRMS/DOCKETS/98fr/04-6480.htm.
FDA Requests Antidepressant Manufacturers to 
Strengthen Warnings
On March 22, 2004, FDA issued a public health advisory that 
cautions physicians, their patients, and families and caregivers 
to closely monitor adults and children with depression. Results 
of antidepressant studies in children since June 2003 appeared 
to suggest an increased risk of suicidal thoughts and actions in 
those children taking certain antidepressants. FDA has initiated 
a review of these reports, but it is not clear whether or not anti-
depressants contribute to suicidal thinking and behavior.
As a result of the studies, FDA is asking manufacturers to 
change the labels of 10 drugs to include stronger cautions and 
warnings to monitor patients for worsening depression and 
the emergence of suicidal ideation. The drugs affected include 
bupropion (Wellbutrin®), citalopram (Celexa™), escitalopram 
(Lexapro™), fluvoxamine (Luvox® – not FDA approved for treat-
ment of depression in the US), fluoxetine (Prozac®), mirtazapine 
(Remeron®), nefazodone (Serzone®), paroxetine (Paxil®), venlax-
afine (Effexor®), and sertraline (Zoloft®). It should be noted that 
Prozac is the only drug approved for use in children with major 
depressive disorder. Prozac, Zoloft, and Luvox are approved for 
pediatric patients with obsessive-compulsive disorder.
Patients taking these antidepressants should be monitored 
for behaviors associated with the drugs such as anxiety, agita-
tion, panic attacks, insomnia, irritability, hostility, impulsivity, 
akathisia, hypomania, and mania. Physicians are urged to closely 
monitor patients with bipolar disorder as monotherapy with 
antidepressants is believed to have the potential to induce manic 
episodes in such patients. A causal relationship has not been 
established between physical symptoms and suicidal ideation; 
however, medications may need to be discontinued when the 
symptoms are severe, abrupt in onset, or were not part of the pre-
senting symptoms. Further information can be found on CDER’s 
Web site: www.fda.gov/cder/drug/antidepressants/default.htm.
Let Past Experience with Chloral Hydrate Syrup 
Guide its Safe Use
This column was prepared by the Institute 
for Safe Medication Practices (ISMP). ISMP 
is an independent nonprofit agency that works 
closely with United States Pharmacopeia 
(USP) and FDA in analyzing medication er-
rors, near misses, and potentially hazardous 
conditions as reported by pharmacists and 
other practitioners. ISMP then makes appropriate contacts with 
companies and regulators, gathers expert opinion about preven-
tion measures, then publishes its recommendations. If you would 
like to report a problem confidentially to these organizations, go 
to the ISMP Web site (www.ismp.org) for links with USP, ISMP, 
and FDA. Or call 1-800/23-ERROR to report directly to the 
USP-ISMP Medication Errors Reporting Program. ISMP ad-
dress: 1800 Byberry Rd, Huntingdon Valley, PA 19006. Phone: 
215/947-7797. E-mail: ismpinfo@ismp.org. 
Chloral hydrate can be used safely to sedate pediatric patients 
for diagnostic procedures such as endoscopic procedures, CT 
scans, or MRIs. However, in several error reports over the years 
we have seen the sad stories of fatalities that have occurred after 
excessive doses of the drug were dispensed in error. Typically, 
deaths have occurred in cases where the order was not clear or 
when untrained individuals, both staff and parents, were involved 
without adequate supervision or the knowledge that they were 
administering an overdose. In some cases, to save time, chloral 
hydrate has been prescribed for use at home prior to travel to 
the practice site. In one instance, a 500 mg/5 mL concentration 
was dispensed instead of 250 mg/5 mL, which also is available. 
Unfortunately, the dose was prescribed by volume (teaspoonful), 
which made detection of the twofold overdose impossible. In 
another incidence, 120 mL of syrup was incorrectly dispensed 
instead of the prescribed 12 mL. The label instructed the mother 
to give her child the entire bottle, which she did. Without trained 
personnel and emergency equipment present to treat these ac-
cidental overdoses, the children in both cases died. 
Recently the tragedy happened again. A prescription was writ-
ten for a 17-month-old child; the pharmacist read the directions 
as “30 cc before office visit” and instructed the mother to give 
her child that amount. 
In truth, the physician 
wanted the child to 
receive 500 mg 30 
minutes before the of-
fice visit. The double 
hash-mark symbol 
("), which the physi-
cian intended to mean minutes, was misread as cc. Actually, a 
double hash mark stands for seconds; a single hash mark (') is 
used for minutes. Neither symbol should be used in medicine, 
however, because not everyone understands their meaning.
Errors also happen in diagnostic areas where technical support 
personnel often administer oral conscious sedation even though 
they are not properly trained. In some cases, an ambiguous phy-
sician order such as “give chloral hydrate 5 cc prn sedation” or 
“. . . prn agitation,” rather than a specific milligram amount and 
maximum dose, has led to events where multiple doses of chloral 
hydrate were dispensed from the supply available to personnel. 
By the time the child fell asleep, the amount administered was 
a massive overdose leading to respiratory arrest. 
Please consider reviewing your process for dispensing oral 
liquids used for conscious sedation in children, whether to a 
medical facility or to a family member. We suggest that the fol-
lowing precautions, in addition to package insert recommenda-
tions, be employed. Advise physicians that the drug should not 
be prescribed by volume (eg, “5 mL,” “one teaspoonful,” etc). 
There are two available concentrations of this drug. Instead, the 
specific milligram dose should be expressed. The prescription 
should state that it is for pre-procedure sedation. In hospital 
situations or when pharmacies dispense to health care facilities, 
prescriptions are best dispensed for each patient in labeled, unit-
dose, oral syringes; providing the product in bulk packages as 
floor stock is less safe. We believe it is safest for pharmacists 
to not dispense prescriptions for patient use in the home when 
it is for pre-procedure sedation. Should the caregiver receive 
such a prescription, he or she should be advised that they are 
safest for the dose to be administered where the procedure will 
be performed. Official labeling for Versed® Syrup, another drug 
used for conscious sedation in children, notes that the syrup is 
intended for use only in monitored settings, never the home. 
Also, as noted in the product’s boxed warning, only health care 
professionals trained in conscious sedation procedures and au-
thorized to administer conscious sedation drugs should do so. 
Careful monitoring by direct visual observation is necessary and 
age-/size- appropriate resuscitation equipment must be readily 
available. The American Academy of Pediatrics agrees; the 
Academy’s current “Guidelines for Monitoring and Management 
of Pediatric Patients During and After Sedation for Diagnostic 
and Therapeutic Procedures” (Pediatrics 2002; 110:836-838) 
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recommend that children should not receive sedative or anx-
iolytic medications without supervision by skilled medical 
personnel. These medications should be administered by, or in 
the presence of, individuals skilled in airway management and 
cardiopulmonary resuscitation and administered in a health care 
facility where appropriate monitoring, including continuous 
pulse oximetry, can be instituted. 
One final argument for administering children’s sedation on site is 
to ensure proper timing in case of unpredictable schedule delays.
NABP Releases Updated NAPLEX Blueprint 
NABP has released the updated blueprint for the North 
American Pharmacist Licensure Examination™ (NAPLEX®). 
The blueprint is available for viewing on NABP’s Web site, 
www.nabp.net, as of September 2004. Examinations based on 
the updated blueprint will be administered beginning spring 2005.
Changes to the NAPLEX blueprint include the addition of 
competency statements addressing dietary supplements and phar-
macotherapeutic equivalency as well as integration of the skill of 
communicating with patients and other health care providers in the 
entire examination blueprint instead of focusing it within a single 
competency area as with the current NAPLEX. The examination 
continues to consist of three major areas that are divided into 
several competency and subcompetency statements.
The updated blueprint and competency statements require a 
new passing standard. However, the NAPLEX continues to be a 
computer-adaptive examination that requires a scaled score of 75 
or greater to pass. Calculation of the score is the same as in the 
past: the score is calculated by first determining the candidate’s 
ability level on the NAPLEX and then comparing this to the 
predetermined minimum acceptable ability level established 
for the NAPLEX. The new passing standard will go into effect 
along with the updated blueprint in spring 2005.
For more information about the NAPLEX, contact the Cus-
tomer Service Department by calling 847/391-4406 or visit the 
Association’s Web site at www.nabp.net.
December 2004 FPGEE Date and Location 
Announced
On December 4, 2004, NABP will again administer a paper-
and-pencil Foreign Pharmacy Graduate Equivalency Exami-
nation® (FPGEE®). The examination is being offered at three 
United States locations: Northlake (Chicago area), IL; New York, 
NY; and San Mateo, CA. Candidates who have been accepted to 
sit for the December 4, 2004 administration were mailed their 
admission tickets in early fall. 
To prepare for the December examination, candidates may 
take the Pre-FPGEE™, a Web-based practice examination for the 
FPGEE. The practice examination is accessible at www.nabp.net 
and www.pre-fpgee.com.
For more information on the FPGEE, visit NABP’s Web site 
at www.nabp.net.
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support staff up to a 4 to 1 ratio, provided it meets with 
the approval of the pharmacist supervising the technician. 
PTCB-certified technicians can also take on additional 
responsibilities in the pharmacy such as, under certain cir-
cumstances, accepting oral prescription orders and assisting 
with the handling of Schedule II controlled substances.
Pharmacy technicians are important to the profession 
of pharmacy. With the expanded roles and responsibilities 
technicians now have, pharmacists should have a greater 
opportunity to provide counseling, intervention, and other 
pharmaceutical care services to their patients. 
Please refer to Board Regulations at 247 CMR § 8.02 
for more details.
5. Joint Guideline on Pharmacist 
Administration of Influenza Vaccine 
Minimum Requirements (replaces Policy 
2004-01)
The DPH recently lifted the pilot status of the pharmacist 
influenza vaccine program. Regulations of the DPH – Drug 
Control Program permit pharmacists, with appropriate 
training, to administer influenza vaccine to individuals 18 
years of age and over. Further information regarding admin-
istration requirements may be viewed at www.mass.gov/reg/
boards/ph (Rules & Regulations – “Board Policies”).
However, pharmacists should be mindful that on Oc-
tober 13, 2004, the Massachusetts Commissioner of DPH 
(Christine Ferguson) issued an order establishing the rules 
and priorities for the distribution and use of the vaccine. 
The order as well as the latest information about the in-
fluenza vaccine situation is posted on DPH’s Web site at 
www.mass.gov/dph.
6. Board Proposes Regulations to 
Improve Patient Outcomes 
On November 9, 2004, the Board held a public hearing 
on proposed amendments to its regulations and added a new 
section requiring all pharmacies to establish a Continuous 
Quality Improvement Program.
*15.02: Continuous Quality Improvement 
Program
(1) Continuous Quality Improvement Program Require-
ments. Each pharmacy shall establish a Continuous 
Quality Improvement (CQI) Program for the purpose 
of detecting, documenting, assessing and preventing 
Quality-Related Events (QREs). At a minimum, a 
CQI program shall include provisions to:
(a) designate an individual or individuals respon-
sible for monitoring CQI Program compliance 
with the requirements of 247 CMR 15.00; 
(b) identify and document QREs; 
(c) minimize impact of QREs on patients;
(d) analyze data collected in response to QREs to 
assess causes and any contributing factors; 
(e) use the findings of the analysis to formulate an 
appropriate response and develop pharmacy 
systems and workflow processes designed to 
prevent QREs; and
(f) provide ongoing professional education at 
least annually in the area of CQI to pharmacy 
personnel. 
15.03: Quality Related Event Discovery,  
Notification and Documentation.
(1) QRE Discovery and Notification. All pharmacy 
personnel shall be trained to bring any QRE to the 
attention of the pharmacist on duty or the pharmacist 
Manager of Record immediately upon discovery. The 
pharmacist who has discovered or been informed of 
a QRE shall immediately provide:
(a) notification to the patient or patient’s repre-
sentative, the prescriber (if indicated in the 
professional judgment of the pharmacist) and 
other members of the healthcare team;
(b) directions for correcting the error; and 
(c) instructions for minimizing the negative im-
pact on the patient. 
(2) QRE Documentation.  
(a) A QRE shall be initially documented by the 
pharmacist who has discovered or been in-
formed of the QRE on the same day the QRE is 
discovered by or described to the pharmacist. 
(b) QRE documentation shall include a descrip-
tion of the event that is sufficient to permit 
categorization and analysis of the event.  QRE 
documentation shall include:
1. the date when the pharmacist discovered 
or received notification of the QRE and 
the name of the person who notified the 
pharmacy;
2. the names and titles of the persons record-
ing the QRE information and performing 
the QRE analysis;
3. a description of the QRE reviewed; and 
4. documentation of the contact with the 
patient, or patient’s representative, and 
prescribing practitioner (if indicated in 
the professional judgment of the pharma-
cist), and other members of the health-
care team.
Continued on page 5
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(3) QRE Analysis and Response.
(a) QRE Analysis. The investigative and other per-
tinent data collected in response to QREs shall 
be analyzed, individually and collectively, to 
assess the cause and any contributing factors 
such as system or process failures. The QRE 
analysis and assessment shall include:
1. a consideration of the effects on quality 
assurance related to workflow processes, 
technological support, personnel training 
and staffing levels; 
2. any recommended remedial changes to 
pharmacy policies, procedures, systems, 
or processes; and
3. the development of indicators that identify 
means against which a pharmacy’s program 
intends to measure its standards over a 
designated period of time. 
(b)  Response. Each pharmacy shall inform phar-
macy personnel of changes to pharmacy poli-
cies, procedures, systems, or processes resulting 
from recommendations generated by the CQI 
Program.
15.04: Records
(1) Each pharmacy shall maintain a written copy of its 
CQI Program description on the pharmacy prem-
ises.  The CQI Program description shall be readily 
available to all pharmacy personnel.
(2) Each pharmacy shall maintain a record of all QREs 
for a minimum period of two years from the date 
of the QRE report.  
(3) QRE records shall be maintained in an orderly 
manner and filed by date.  
(4) QRE records may be stored at a site other than the 
pharmacy where the QRE occurred. 
*As presented for public hearing on November 9, 2004. 
Following the hearing, revisions could take place; please 
check the Board’s Web site.
7. Reminder to All Pharmacies Employing 
Interns
All pharmacy interns are required to be registered by the 
Board prior to commencing internship. The Board issues 
to pharmacy interns a registration certificate, which should 
be shown to the preceptor prior to the preceptor agreeing 
to supervise them. 
8. Pharmacist License Renewals and 
Continuing Education Reminder  
License renewal applications were recently mailed 
October 22, 2004 – please consider the consequences of 
signing a renewal under the pains and penalties of per-
jury only after you have physically verified that all your 
continuing education units are in compliance with Board 
regulations at 247 CMR § 4.00 et seq.
Before signing, please conduct a thorough review of 2003 
and 2004 continuing education (CE) certificates of comple-
tion to ensure full compliance with Board regulations set 
forth at 247 CMR, §4.03 (www.state.mass.gov/dpl/boards/
ph/cmr.htm). 
Each calendar year a pharmacist shall complete a mini-
mum of 15 contact hours of CE, of which at least two contact 
hours shall be in the area of pharmacy law, and not more 
than 10 contact hours shall be acquired through home study 
and or other mediated instruction. You are reminded that CE 
programs must be approved by the Accreditation Council 
for Pharmacy Education, or a state board of pharmacy, or 
recognized as Category I Continuing Medical Education by 
the American Medical Association. The Board recommends 
that pharmacists participate in CE programs directly related 
to their practice setting to ensure continued competence in 
their respective areas of specialization. 
Promptly return the completed and signed application 
renewal and required fee of $75 made payable to the “Com-
monwealth of Massachusetts” to the Board in the envelope 
provided. If you do not receive your renewal application 
and/or have questions related to CE requirements, please 
contact the Board at 617/727-9953. A $57 late filing fee 
must accompany any renewal application postmarked after 
December 31, 2004. Please do not send in your certificates 
of CE completion along with the renewal application.
Pharmacists should be mindful that a Board waiver 
provision exists wherein licensees unable to complete req-
uisite CE due to extenuating circumstances and/or physical 
disability may submit a detailed statement to the Board, 
signed under penalties of perjury, for consideration related 
to renewal status. Please be advised that the Board will 
conduct a random CE audit to assess compliance during the 
first quarter of 2005.    
For more information regarding CE, please review re-
lated policy references available on the Board’s Web site at 
www.mass.gov/reg/boards/ph (Rules & Regulations – 
 “Board Policies”): Policy 98-002 regarding CE Audits and 
Compliance, Policy 98-004 concerning Non-traditional 
PharmD Programs, and Policy 98-006 addressing Canadian 
Council on Continuing Pharmaceutical Education and Policy 
2000-05 related to Board-approved CE programs. 
Please consider providing feedback to the Board about 
your comments/suggestions about this and future Newslet-
ters. Remember, this Newsletter is for you, so feel free to 
send recommendations for future Newsletters by e-mail to: 
charles.young@state.ma.us or james.d.coffey@state.ma.us.
Thank you.
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